aTyr Pharma's ATYR2810 reduces osteosarcoma tumor growth in preclinical studies
ATYR•aTyr Pharma said its NRP2-targeting antibody ATYR2810 reduced osteosarcoma tumor growth and lung metastases in mouse studies, with no evidence of overt toxicity. Results were scheduled for presentation November 19, 2026, at a meeting in Seoul.
1. Preclinical results
The antibody’s anti-tumor effects persisted after treatment was withdrawn, and the mouse studies showed no evidence of overt toxicity. ATYR2810 remains in preclinical development; nonhuman primate toxicology testing and manufacturing have been completed.




